Sotorasiib Dosing Guide: Quick Facts on Dosage, Usage and Precautions

Sotorasib (Sotorasib, trade name Lumakras) developed and produced by Amgen is the world's first targeted therapy for lung cancer targeting the KRAS G12C mutation, bringing new hope for treatment to many patients. To ensure patients can take this medicine accurately and safely, the following is a streamlined dosing guide covering dosage, usage, and key precautions.

1. Dosage and administration method

1. Recommended dose: The recommended daily dose of sotoraxib is960 milligrams (mg), which is eight 120 mg (mg) tablets.

2. How to take: Please swallow the tablet whole and avoid chewing, crushing or dividing. You can choose to take it with or without food. Food will not affect the absorption of the medicine. In order to keep the blood concentration stable, it is recommended to take it at the same time every day.

2. Coping with special situations

1. Handling of missed doses: If you miss a dose, please take it as soon as possible. However, if it has been more than 6 hours, there is no need to take a supplementary dose. You only need to take the next dose at the normal time the next day. Never take two doses at the same time to make up for a missed dose.

2. Difficulty in swallowing: For patients who have difficulty swallowing the whole tablet, the daily dose can be put into 120mL of non-carbonated room temperature water. After the tablets become small pieces (note that the tablets will not completely dissolve), drink it immediately or within 2 hours. Then add 120 mL of water and drink up to ensure a complete dose.

3. Side Effect Monitoring

Sotorasiib may cause side effects such as diarrhea, nausea, vomiting, musculoskeletal pain, fatigue, and liver damage. During medication, please pay close attention to your physical condition and report any discomfort to your doctor immediately. Your doctor may adjust your dosage or use other treatments based on your specific situation.

4. Key things to note

1. Avoid drug interactions: Sotoracib is a CYP3A4 substrate. Please avoid simultaneous use with strong CYP3A4 inducers (such as rifampicin, phenobarbital).

2. Medication for special groups: Patients with hepatic insufficiency should use medication with caution according to the degree of liver function impairment, and adjust the dose if necessary. No dose adjustment is usually required in patients with renal impairment, but caution should be used in patients with severe renal impairment. The dosage for elderly patients is the same as for adults, but adverse reactions need to be closely monitored. There is currently a lack of safety and efficacy data in patients under 18 years of age and use is not recommended.

3. Storage conditions: Please store Sotoraxibu in a dry, well-ventilated and dark place, avoiding extreme high or low temperatures.

In short, sotorasiib, as a targeted drug for lung cancer targetingKRAS G12C mutation, provides patients with a new treatment option. To ensure the safety and effectiveness of medication, be sure to follow your doctor's instructions, take it in strict accordance with the recommended dosage and usage, and pay close attention to your physical condition. At the same time, paying attention to the storage conditions of drugs and avoiding drug interactions are also key to ensuring therapeutic effects. Currently, the drug is sold overseas. The original drug is more expensive, while the generic drug is relatively economical. Patients can choose the appropriate version according to their own needs.